Mycobacterium tuberculosis antigen-specific CD4+ T cell receptor – MHC class II–peptide complex (TCR-pMHCII (Mtb-specific))

The Mycobacterium tuberculosis (Mtb) antigen-specific CD4+ T cell receptor – MHC class II–peptide complex is the fundamental molecular unit of adaptive immune recognition in tuberculosis. It consists of a T cell receptor (TCR) on a CD4+ helper T cell binding to a peptide fragment derived from Mtb proteins (such as ESAT-6, CFP-10, or Ag85B) presented by a Major Histocompatibility Complex (MHC) class II molecule on an antigen-presenting cell. This interaction triggers a signaling cascade that activates the T cell to proliferate and secrete Th1-type cytokines, primarily interferon-gamma (IFN-gamma) and tumor necrosis factor (TNF). These cytokines are critical for activating infected macrophages, enhancing their ability to kill intracellular mycobacteria through mechanisms like phagosome-lysosome fusion and the production of reactive oxygen species. Mtb has evolved several strategies to evade this recognition, including the inhibition of MHC class II expression and interference with antigen processing. Consequently, this complex is the primary target for the development of next-generation subunit vaccines, mRNA vaccines, and diagnostic assays like the Interferon-Gamma Release Assay (IGRA).

Other names

TCR-pMHCII complexMtb-specific immunological synapseCD4+ T cell-MHC II-peptide complexMtb-specific TCR-pMHCIIAntigen-specific T cell receptor complex

Vaccines and immunotherapies target this complex by providing specific Mtb antigens that are processed and presented by MHC class II molecules to prime or boost the population of antigen-specific CD4+ T cells. Upon recognition of the pMHCII complex by the TCR, these T cells differentiate into Th1 effectors that secrete IFN-gamma and TNF, which activate macrophages to restrict Mtb replication and prevent disease progression.